Antengene Voluntarily Lowers the Price of XPOVIO® in China to Allow More Patients with Multiple Myeloma to Benefit from the Drug

Shanghai and Hong Kong, PRC, August 29, 2023 — Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), today introduced a round of **voluntary price cut for XPOVIO®** (selinexor) in an effort to improve the drug's accessibility and affordability for patients paying for their treatment out-of-pocket, thus allowing more patients with multiple myeloma (MM) in China to benefit from the drug.

This voluntary price cut will lower the price of XPOVIO® in 20mg * 12 tablets/box **from RMB22,435 to RMB14,135**, and the price of XPOVIO® in 20mg * 16 tablets/box from **RMB29,600 to RMB18,649.67**, by a ratio of approximately 37%. To allow patients to benefit from this price cut as soon as possible, Antengene will update the list-price for XPOVIO® across the Mainland of China and advise direct-to-patient (DTP) and retail pharmacies in the country to make adjustments to the drug's retail prices.

上海市长宁区中山西路 1065 号 SOHO 中山广场 B 座 1206-1209 室
Suite 1206-1209, Building B, SOHO Plaza, 1065 West Zhongshan Road, Shanghai 200051, China
Tel: (86) 021 3250 1095
Fax: (86) 021 3250 1062
www.antengene.com

XPOVIO® is world's first approved orally-available selective inhibitor of the nuclear export protein (XPO1) that utilizes a novel mechanism of action. Since approved in the Mainland of China in December 2021, XPOVIO® was commercially launched in the country in May 13, 2022, for the treatment of patients relapsed/refractory MM (R/R MM).

Dr. Jay Mei, Antengene's Founder, Chairman and CEO, said, "MM is a malignancy caused by the dysregulated proliferation of plasma cells. In recent years, we have seen notable progress in the treatment of R/R MM. However, R/R MM remains largely incurable disease that is prone to relapses, therefore continues to represent a huge unmet medical need. XPOVIO®, an oral drug utilizing a novel mechanism of action, offers significant efficacy and clinically meaningful survival benefits to patients. While introducing this round of voluntary price cut with the aim of improving the drug's affordability for out-of-pocket patients, we are in active preparation to facilitate a potential inclusion of XPOVIO® into China's National Reimbursement Drug List (NRDL), which once achieved, will further improve the accessibility of the drug to patients in the Mainland of China. Meanwhile, we will continue to explore XPOVIO®'s potential for indication expansions in

order to bring an effective, accessible and affordable novel treatment option to more patients in the APAC region and across the globe."

About Antengene

Antengene Corporation Limited (**"Antengene" ,** SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of **"Treating Patients Beyond Borders" .**

Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, South Korea, Singapore and Australia.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2022, and the documents subsequently submitted to the Hong Kong Stock Exchange.